Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Extavia

- PMLiVE

Bayer’s Nexavar recommended for thyroid cancer in EU

CHMP backs extra indication for cancer drug

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

National Institute for Health and Care Excellence NICE logo

NICE backs two cancer drugs

Boehringer’s Giotrif and Janssen’s Velcade given final go-ahead for NHS use

- PMLiVE

Merck Serono CEO joins L’Oreal board

Belén Garijo named independent director at beauty company

Novartis building

Novartis pays $16bn for GSK’s oncology portfolio

Swiss company strikes series of deals, including one to step away from vaccines

National Institute for Health and Care Excellence NICE logo

NICE gives partial backing to Ferring’s prostate cancer drug

Firmagon on course for use on NHS in England and Wales

- PMLiVE

Changing the guard at Novartis’ Sandoz and Alcon units

Richard Francis joins from Biogen Idec and Kevin Buehler retires

Novartis building

Novartis replaces execs in Japan after investigation

Finds irregular practices in clinical trials programme

Roche - Basel

NICE reverses decision to restrict Tarceva access

Roche says “voices of clinicians and patients have been heard”

- PMLiVE

Doctors criticise FDA over Lemtrada rejection

Say Sanofi/Genzyme’s MS drug should have been approved

Novartis day

Novartis’ dual-action heart failure drug aces trial

Ends LCZ696 trial early on good results

National Institute for Health and Care Excellence NICE logo

Final NICE ‘no’ for J&J’s Stelara in psoriatic arthritis

Committee says drug is more expensive and less effective than TNF alpha inhibitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links